Thursday 29 November 2018

Combination Immunotherapy Could Improve Outcome in Melanoma

A triple combination cancer immunotherapy based regimen containing adoptive T cell therapy, a PIM kinase inhibitor, and a PD-1 inhibitor could improve survival in a mouse model of melanoma


from Medindia Health News https://ift.tt/2QpNhck

No comments:

Post a Comment